Illumina DNA test for Down Syndrome more accurate

Illumina's (ILMN +1.3%) cell-free DNA testing technology was more accurate than traditional techniques in diagnosing Down syndrome and Edwards syndrome.

The false-positive rate of Illumina's cfDNA product was 0.3% for Down syndrome vs 3.6% for standard screening, and 0.2% for Edwards vs 0.6%.

The study could lead to the testing in expectant mothers beyond only those considered at high risk for having babies with Down and Edwards syndromes.

The results of the study were published in the New England Journal of Medicine.

Three other companies in the U.S. provide cfDNA testing - Sequenom (SQNM +3%), Ariosa Diagnostics and Natera.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs